BACKGROUND: There have been many randomised trials of adjuvant tamoxifen among
women with early breast cancer, and an updated overview of their results is presented …

Breast cancer is a heterogeneous disease that affects one anatomic site, yet is
phenotypically variable. 1, 2 The identification of different biological subtypes occurs …

Background The administration of endocrine therapy for 5 years substantially reduces
recurrence rates during and after treatment in women with early-stage, estrogen-receptor …

Background For women with oestrogen receptor (ER)-positive early breast cancer, treatment
with tamoxifen for 5 years substantially reduces the breast cancer mortality rate throughout …

Background As trials of 5 years of tamoxifen in early breast cancer mature, the relevance of
hormone receptor measurements (and other patient characteristics) to long-term outcome …

Background: The finding of a decrease in contralateral breast cancer incidence following
tamoxifen administration for adjuvant therapy led to the concept that the drug might play a …

Background In hormone-dependent breast cancer, five years of postoperative tamoxifen
therapy—but not tamoxifen therapy of longer duration—prolongs disease-free and overall …

ContextRaloxifene hydrochloride is a selective estrogen receptor modulator that has
antiestrogenic effects on breast and endometrial tissue and estrogenic effects on bone, lipid …

Breast cancer is the most common cancer in women in the Western world. Because breast
cancer is estrogen-dependent, reducing estrogen secretion by oophorectomy …

The FACIT trial of folic acid supple mentation in older adults by Jane Durga and colleagues
(Jan 20, p 208) 1 adds to the growing evidence of the importance of folate to the nervous …